Ramucirumab Use in Combination With Paclitaxel in Gastric or Gastroesophageal Junction Adenocarcinoma; Temporary Authorization for Use (ATU) in France

Expanded access Approved for marketing Eli Lilly and Company

The treating physician/investigator contacts Lilly when, based on their medical opinion, a patient meets the criteria for inclusion in the ATU.

Evaluation	Drug	Modality	Dose	Route
Subject	Paclitaxel	Small molecule	—	Intravenous
Subject	Ramucirumab	Monoclonal antibody	—	Intravenous